S-nitrosoglutathione reductase-dependent p65 denitrosation promotes osteoclastogenesis by facilitating recruitment of p65 to NFATc1 promoter
Bone · 2024
DOI: 10.1016/j.bone.2024.117036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2024. Verfasst von Shumin Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Lab…. Hauptthemen laut MEDLINE: Bone Resorption, Osteolysis, Aldehyde Oxidoreductases. Die Arbeit nennt 86 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Vedecká Grantová Agentúra MŠVVaŠ SR a SAV, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Osteoclasts, the exclusive bone resorptive cells, are indispensable for bone remodeling. Hence, understanding novel signaling modulators regulating osteoclastogenesis is clinically important. Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) is a master transcription factor in osteoclastogenesis, and binding of NF-κB p65 subunit to NFATc1 promoter is required for its expression. It is well-established that DNA binding activity of p65 can be regulated by various post-translational modifications, including S-nitrosation. Recent studies have demonstrated that S-nitrosoglutathione reductase (GSNOR)-mediated protein denitrosation participated in cell fate commitment by regulating gene transcription. However, the role of GSNOR in osteoclastogenesis remains unexplored and enigmatic. Here, we investigated the effect of GSNOR-mediated denitrosation of p65 on osteoclastogenesis. Our results revealed that GSNOR was up-regulated during osteoclastogenesis in vitro. Moreover, GSNOR inhibition with a chemical inhibitor impaired osteoclast differentiation, podosome belt formation, and bone resorption activity. Furthermore, GSNOR inhibition enhanced the S-nitrosation level of p65, precluded the binding of p65 to NFATc1 promoter, and suppressed NFATc1 expression. In addition, mouse model of lipopolysaccharides (LPS)-induced calvarial osteolysis was employed to evaluate the therapeutic effect of GSNOR inhibitor in vivo. Our results indicated that GSNOR inhibitor treatment alleviated the inflammatory bone loss by impairing osteoclast formation in mice. Taken together, these data have shown that GSNOR activity is required for osteoclastogenesis by facilitating binding of p65 to NFATc1 promoter via promoting p65 denitrosation, suggesting that GSNOR may be a potential therapeutic target in the treatment of osteolytic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan Univer…
- School of Stomatology, Wuhan University, Wuhan 430079, China.
Förderung
- National Natural Science Foundation of China
- Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- Fundamental Research Funds for the Central Universities
- National College Students Innovation and Entrepreneurship Training Program
Zitieren
APA
Liu, S., Lu, Q., Wang, M., Guo, H., Wang, Y., Nong, J., Wang, S., Xia, H., Xia, T., & Sun, H. (2024). S-nitrosoglutathione reductase-dependent p65 denitrosation promotes osteoclastogenesis by facilitating recruitment of p65 to NFATc1 promoter. Bone. https://doi.org/10.1016/j.bone.2024.117036
Vancouver
Liu S, Lu Q, Wang M, Guo H, Wang Y, Nong J, et al. S-nitrosoglutathione reductase-dependent p65 denitrosation promotes osteoclastogenesis by facilitating recruitment of p65 to NFATc1 promoter. Bone. 2024. doi:10.1016/j.bone.2024.117036
BibTeX
@article{Liu2024,
author = {Liu, Shumin and Lu, Qian and Wang, Min and Guo, Huilin and Wang, Yiwen and Nong, Jingwen and Wang, Shuo and Xia, Haibin and Xia, Ting and Sun, Huifang},
title = {S-nitrosoglutathione reductase-dependent p65 denitrosation promotes osteoclastogenesis by facilitating recruitment of p65 to NFATc1 promoter},
journal = {Bone},
year = {2024},
doi = {10.1016/j.bone.2024.117036}
}
EUVIMED